The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women.

Thompson JL, Butterfield GE, Marcus R, Hintz RL, Van Loan M, Ghiron L, Hoffman AR

The Journal of clinical endocrinology and metabolism1 Jun 1995Cited by 91 (Europe PMC)

PMID7539817DOI10.1210/jcem.80.6.7539817PepBankPUB-07539817

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialMechanism
In elderly women, serum IGF-I increased significantly in all groups, including both rhIGF-I groups.
In plain wordsIn elderly women, serum IGF-I increased in all groups, including both rhIGF-I groups.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSerum IGF-I
Study
n = 16
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.015 and 0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
All groups experienced a significant increase in serum IGF-I and IGFBP-3 levels over the treatment period, accompanied by significant decreases in IGF-II (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to determine the effects of recombinant human GH (rhGH; 0.025 mg/kg.day) and one of two doses of recombinant human insulin-like growth factor-I (rhIGF-I; 0.015 and 0.060 mg/kg, twice daily) on body composition in elderly women.
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981701
02HumanRandomized controlled trialMechanism
In elderly women, serum IGFBP-3 increased significantly in all groups, including both rhIGF-I groups.
In plain wordsIn elderly women, serum IGFBP-3 increased in all groups, including both rhIGF-I groups.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSerum IGFBP-3
Study
n = 16
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.015 and 0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
All groups experienced a significant increase in serum IGF-I and IGFBP-3 levels over the treatment period, accompanied by significant decreases in IGF-II (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981702
03HumanRandomized controlled trialMechanism
In elderly women, serum IGF-II decreased significantly in all groups, including both rhIGF-I groups.
In plain wordsIn elderly women, serum IGF-II decreased in all groups, including both rhIGF-I groups.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSerum IGF-II
Study
n = 16
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.015 and 0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Measurements
P value for serum IGF-II decrease
< 0.05 p value
All groups, decrease over the treatment period
Source sentences
Summary
All groups experienced a significant increase in serum IGF-I and IGFBP-3 levels over the treatment period, accompanied by significant decreases in IGF-II (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981703
04HumanRandomized controlled trialEfficacy outcome
In elderly women, fat mass decreased in all groups, including both rhIGF-I groups.
In plain wordsIn elderly women, fat mass decreased in all groups, including both rhIGF-I groups.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFat mass
Study
n = 16
Outcome group
Body composition · Metabolic and weight
Studied dose
0.015 and 0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
Fat mass decreased in all groups, with significant increases in lean body mass and nitrogen retention occurring in the high dose IGF and GH groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981704
05HumanRandomized controlled trialSafety outcome
In elderly women, low-dose rhIGF-I was well tolerated.
In plain wordsIn elderly women, low-dose rhIGF-I was well tolerated.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableTolerability
Study
n = 6
Outcome group
Adverse events · Whole body
Studied dose
0.015 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
The low IGF dose was well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981713
06HumanRandomized controlled trialEfficacy outcome
In elderly women, high-dose rhIGF-I significantly increased lean body mass.
In plain wordsIn elderly women, high-dose rhIGF-I increased lean body mass.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseLean body mass
Study
n = 5
Outcome group
Body composition · Metabolic and weight
Studied dose
0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
Fat mass decreased in all groups, with significant increases in lean body mass and nitrogen retention occurring in the high dose IGF and GH groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981705
07HumanRandomized controlled trialEfficacy outcome
In elderly women, high-dose rhIGF-I significantly increased nitrogen retention.
In plain wordsIn elderly women, high-dose rhIGF-I increased nitrogen retention.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseNitrogen retention
Study
n = 5
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
Fat mass decreased in all groups, with significant increases in lean body mass and nitrogen retention occurring in the high dose IGF and GH groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981706
08HumanRandomized controlled trialSafety outcome
In elderly women, headaches were among the side-effects reported in the GH and high-dose rhIGF-I groups.
In plain wordsIn elderly women, headaches were among the side-effects reported in the GH and high-dose rhIGF-I groups.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableHeadaches
Study
n = 5
Outcome group
Adverse events · Nervous system and cognition
Studied dose
0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
These anabolic changes were accompanied by numerous negative side-effects in the GH and high dose IGF groups, including headaches, lethargy, joint swelling/pain, and bloatedness.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981709
09HumanRandomized controlled trialSafety outcome
In elderly women, lethargy was among the side-effects reported in the GH and high-dose rhIGF-I groups.
In plain wordsIn elderly women, lethargy was among the side-effects reported in the GH and high-dose rhIGF-I groups.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableLethargy
Study
n = 5
Outcome group
Adverse events · Whole body
Studied dose
0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
These anabolic changes were accompanied by numerous negative side-effects in the GH and high dose IGF groups, including headaches, lethargy, joint swelling/pain, and bloatedness.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981710
10HumanRandomized controlled trialSafety outcome
In elderly women, joint swelling/pain was among the side-effects reported in the GH and high-dose rhIGF-I groups.
In plain wordsIn elderly women, joint swelling or pain was among the side-effects reported in the GH and high-dose rhIGF-I groups.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableJoint swelling/pain
Study
n = 5
Outcome group
Adverse events · Musculoskeletal
Studied dose
0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
These anabolic changes were accompanied by numerous negative side-effects in the GH and high dose IGF groups, including headaches, lethargy, joint swelling/pain, and bloatedness.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981711
11HumanRandomized controlled trialSafety outcome
In elderly women, bloatedness was among the side-effects reported in the GH and high-dose rhIGF-I groups.
In plain wordsIn elderly women, bloating was among the side-effects reported in the GH and high-dose rhIGF-I groups.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableBloatedness
Study
n = 5
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.060 mg/kg twice daily · 4 weeksAs given in this study (human).
Source sentences
Summary
These anabolic changes were accompanied by numerous negative side-effects in the GH and high dose IGF groups, including headaches, lethargy, joint swelling/pain, and bloatedness.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
Report a problemFND-0753981712

Studies that did not test the peptide alone2

In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 (mecasermin).

12HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In elderly women given rhGH or rhIGF-I (groups not reported separately), total body water did not change.
In plain wordsIn elderly women given growth hormone or IGF-I, total body water did not change; groups were not reported separately.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeTotal body water
Study
n = 16
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Total body water did not change, whereas increases observed in intracellular fluid approached significance (P = 0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0753981707
13HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In elderly women given rhGH or rhIGF-I (groups not reported separately), intracellular fluid increases approached significance (P = 0.06).
In plain wordsIn elderly women given growth hormone or IGF-I, rises in intracellular fluid came close to significance; groups were not reported separately.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeIntracellular fluid
Study
n = 16
Outcome group
Body composition · Metabolic and weight
Measurements
P value for intracellular fluid increase
0.06 p value
rhGH or rhIGF-I, groups not reported separately, increase over the treatment period
Source sentences
Summary
Total body water did not change, whereas increases observed in intracellular fluid approached significance (P = 0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy elderly women (mean age +/- SEM, 71.9 +/- 1.3 yr) were randomly assigned to receive either rhGH (GH; n = 5), low dose rhIGF-I (n = 6), or high dose rhIGF-I (n = 5).
Summary · context
A 2-week predrug baseline period was followed by 4 weeks of hormone treatment, with a standardized diet fed throughout.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0753981708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.